Friday, May 16, 2014

basic research 2

Secondary malignancy

When a receptor is permanently blocked Or destroyed
When a gene is over stimulated
When bypass activation exist and may involve an important pathways
Addition of immunomodulator to an alkylating agent. Seems of concern

Pomalidomide
Dinaciclib
ARRY 520

For CLL
FCR remains standar of care
And bendamustne rituxan an alternative
And ibrutinib for bulky diseases

 Secondary tumor produced by a known gene alteration
Should be treated by blocking a gene within the same pathway either upstream or down stream.  Instead of using standard of care for that tumor.

In pancreatic cancers most of the intervention
Have not confronted  the NF kB

Review the NOTCH pathway

Spark level associate Ted with good prognosis in pancreatic cancer
Spar level
Post a Comment